Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
5,078
archived clinical trials in
Major Depression Disorder (MDD)

Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder
A Double-Blind, Placebo-Controlled, Fixed-Dose Study of Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated:  8/20/2012
Forest Investigative Site 009
2578
mi
from 02139
Orange, CA
Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder
A Double-Blind, Placebo-Controlled, Fixed-Dose Study of Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated: 8/20/2012
Forest Investigative Site 009
2578
mi
from 02139
Orange, CA
Click here to add this to my saved trials
Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder
A Double-Blind, Placebo-Controlled, Fixed-Dose Study of Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated:  8/20/2012
Forest Investigative Site 005
2547
mi
from 02139
Riverside, CA
Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder
A Double-Blind, Placebo-Controlled, Fixed-Dose Study of Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated: 8/20/2012
Forest Investigative Site 005
2547
mi
from 02139
Riverside, CA
Click here to add this to my saved trials
Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder
A Double-Blind, Placebo-Controlled, Fixed-Dose Study of Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated:  8/20/2012
Forest Investigative Site 010
2583
mi
from 02139
Costa Mesa, CA
Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder
A Double-Blind, Placebo-Controlled, Fixed-Dose Study of Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated: 8/20/2012
Forest Investigative Site 010
2583
mi
from 02139
Costa Mesa, CA
Click here to add this to my saved trials
Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder
A Double-Blind, Placebo-Controlled, Fixed-Dose Study of Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated:  8/20/2012
Forest Investigative site 005
1244
mi
from 02139
Pembroke Pines, FL
Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder
A Double-Blind, Placebo-Controlled, Fixed-Dose Study of Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated: 8/20/2012
Forest Investigative site 005
1244
mi
from 02139
Pembroke Pines, FL
Click here to add this to my saved trials
Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder
A Double-Blind, Placebo-Controlled, Fixed-Dose Study of Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated:  8/20/2012
Forest Investigative site 004
1183
mi
from 02139
Tampa, FL
Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder
A Double-Blind, Placebo-Controlled, Fixed-Dose Study of Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated: 8/20/2012
Forest Investigative site 004
1183
mi
from 02139
Tampa, FL
Click here to add this to my saved trials
Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder
A Double-Blind, Placebo-Controlled, Fixed-Dose Study of Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated:  8/20/2012
Forest Investigative Site
925
mi
from 02139
Atlanta, GA
Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder
A Double-Blind, Placebo-Controlled, Fixed-Dose Study of Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated: 8/20/2012
Forest Investigative Site
925
mi
from 02139
Atlanta, GA
Click here to add this to my saved trials
Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder
A Double-Blind, Placebo-Controlled, Fixed-Dose Study of Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated:  8/20/2012
Forest Investigative Site 001
352
mi
from 02139
Towson, MD
Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder
A Double-Blind, Placebo-Controlled, Fixed-Dose Study of Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated: 8/20/2012
Forest Investigative Site 001
352
mi
from 02139
Towson, MD
Click here to add this to my saved trials
Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder
A Double-Blind, Placebo-Controlled, Fixed-Dose Study of Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated:  8/20/2012
Forest Investigative Site
542
mi
from 02139
Cleveland, OH
Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder
A Double-Blind, Placebo-Controlled, Fixed-Dose Study of Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated: 8/20/2012
Forest Investigative Site
542
mi
from 02139
Cleveland, OH
Click here to add this to my saved trials
Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder
A Double-Blind, Placebo-Controlled, Fixed-Dose Study of Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated:  8/20/2012
Forest Investigative site 011
276
mi
from 02139
Broomall, PA
Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder
A Double-Blind, Placebo-Controlled, Fixed-Dose Study of Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated: 8/20/2012
Forest Investigative site 011
276
mi
from 02139
Broomall, PA
Click here to add this to my saved trials
Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder
A Double-Blind, Placebo-Controlled, Fixed-Dose Study of Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated:  8/20/2012
Forest Investigative Site
34
mi
from 02139
Lincoln, RI
Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder
A Double-Blind, Placebo-Controlled, Fixed-Dose Study of Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated: 8/20/2012
Forest Investigative Site
34
mi
from 02139
Lincoln, RI
Click here to add this to my saved trials
Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder
A Double-Blind, Placebo-Controlled, Fixed-Dose Study of Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated:  8/20/2012
Forest Investigative Site
1125
mi
from 02139
Memphis, TN
Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder
A Double-Blind, Placebo-Controlled, Fixed-Dose Study of Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated: 8/20/2012
Forest Investigative Site
1125
mi
from 02139
Memphis, TN
Click here to add this to my saved trials
Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder
A Double-Blind, Placebo-Controlled, Fixed-Dose Study of Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated:  8/20/2012
Forest Investigative Site
1602
mi
from 02139
Houston, TX
Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder
A Double-Blind, Placebo-Controlled, Fixed-Dose Study of Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated: 8/20/2012
Forest Investigative Site
1602
mi
from 02139
Houston, TX
Click here to add this to my saved trials
Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder
A Double-Blind, Placebo-Controlled, Fixed-Dose Study of Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated:  8/20/2012
Forest Investigative Site
2474
mi
from 02139
Bellevue, WA
Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder
A Double-Blind, Placebo-Controlled, Fixed-Dose Study of Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated: 8/20/2012
Forest Investigative Site
2474
mi
from 02139
Bellevue, WA
Click here to add this to my saved trials
Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder
A Double-Blind, Placebo-Controlled, Fixed-Dose Study of Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated:  8/20/2012
Forest Investigative Site #027
2483
mi
from 02139
Seattle, WA
Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder
A Double-Blind, Placebo-Controlled, Fixed-Dose Study of Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated: 8/20/2012
Forest Investigative Site #027
2483
mi
from 02139
Seattle, WA
Click here to add this to my saved trials
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed With Major Depressive Disorder
Status: Enrolling
Updated:  8/30/2012
GSK Investigational Site
2585
mi
from 02139
Cerritos, CA
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed With Major Depressive Disorder
Status: Enrolling
Updated: 8/30/2012
GSK Investigational Site
2585
mi
from 02139
Cerritos, CA
Click here to add this to my saved trials
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed With Major Depressive Disorder
Status: Enrolling
Updated:  8/30/2012
GSK Investigational Site
2572
mi
from 02139
San Diego, CA
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed With Major Depressive Disorder
Status: Enrolling
Updated: 8/30/2012
GSK Investigational Site
2572
mi
from 02139
San Diego, CA
Click here to add this to my saved trials
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed With Major Depressive Disorder
Status: Enrolling
Updated:  8/30/2012
GSK Investigational Site
2597
mi
from 02139
Torrance, CA
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed With Major Depressive Disorder
Status: Enrolling
Updated: 8/30/2012
GSK Investigational Site
2597
mi
from 02139
Torrance, CA
Click here to add this to my saved trials
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed With Major Depressive Disorder
Status: Enrolling
Updated:  8/30/2012
GSK Investigational Site
1017
mi
from 02139
Jacksonville, FL
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed With Major Depressive Disorder
Status: Enrolling
Updated: 8/30/2012
GSK Investigational Site
1017
mi
from 02139
Jacksonville, FL
Click here to add this to my saved trials
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed With Major Depressive Disorder
Status: Enrolling
Updated:  8/30/2012
GSK Investigational Site
1256
mi
from 02139
Miami, FL
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed With Major Depressive Disorder
Status: Enrolling
Updated: 8/30/2012
GSK Investigational Site
1256
mi
from 02139
Miami, FL
Click here to add this to my saved trials
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed With Major Depressive Disorder
Status: Enrolling
Updated:  8/30/2012
GSK Investigational Site
923
mi
from 02139
Atlanta, GA
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed With Major Depressive Disorder
Status: Enrolling
Updated: 8/30/2012
GSK Investigational Site
923
mi
from 02139
Atlanta, GA
Click here to add this to my saved trials
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed With Major Depressive Disorder
Status: Enrolling
Updated:  8/30/2012
GSK Investigational Site
931
mi
from 02139
Marietta, GA
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed With Major Depressive Disorder
Status: Enrolling
Updated: 8/30/2012
GSK Investigational Site
931
mi
from 02139
Marietta, GA
Click here to add this to my saved trials
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed With Major Depressive Disorder
Status: Enrolling
Updated:  8/30/2012
GSK Investigational Site
845
mi
from 02139
Chicago, IL
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed With Major Depressive Disorder
Status: Enrolling
Updated: 8/30/2012
GSK Investigational Site
845
mi
from 02139
Chicago, IL
Click here to add this to my saved trials
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed With Major Depressive Disorder
Status: Enrolling
Updated:  8/30/2012
GSK Investigational Site
849
mi
from 02139
Skokie, IL
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed With Major Depressive Disorder
Status: Enrolling
Updated: 8/30/2012
GSK Investigational Site
849
mi
from 02139
Skokie, IL
Click here to add this to my saved trials
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed With Major Depressive Disorder
Status: Enrolling
Updated:  8/30/2012
GSK Investigational Site
1411
mi
from 02139
Shreveport, LA
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed With Major Depressive Disorder
Status: Enrolling
Updated: 8/30/2012
GSK Investigational Site
1411
mi
from 02139
Shreveport, LA
Click here to add this to my saved trials
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed With Major Depressive Disorder
Status: Enrolling
Updated:  8/30/2012
GSK Investigational Site
389
mi
from 02139
Rockville, MD
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed With Major Depressive Disorder
Status: Enrolling
Updated: 8/30/2012
GSK Investigational Site
389
mi
from 02139
Rockville, MD
Click here to add this to my saved trials
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed With Major Depressive Disorder
Status: Enrolling
Updated:  8/30/2012
GSK Investigational Site
1959
mi
from 02139
Albuquerque, NM
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed With Major Depressive Disorder
Status: Enrolling
Updated: 8/30/2012
GSK Investigational Site
1959
mi
from 02139
Albuquerque, NM
Click here to add this to my saved trials
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed With Major Depressive Disorder
Status: Enrolling
Updated:  8/30/2012
GSK Investigational Site
598
mi
from 02139
Raleigh, NC
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed With Major Depressive Disorder
Status: Enrolling
Updated: 8/30/2012
GSK Investigational Site
598
mi
from 02139
Raleigh, NC
Click here to add this to my saved trials
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed With Major Depressive Disorder
Status: Enrolling
Updated:  8/30/2012
GSK Investigational Site
733
mi
from 02139
Cincinnati, OH
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed With Major Depressive Disorder
Status: Enrolling
Updated: 8/30/2012
GSK Investigational Site
733
mi
from 02139
Cincinnati, OH
Click here to add this to my saved trials
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed With Major Depressive Disorder
Status: Enrolling
Updated:  8/30/2012
GSK Investigational Site
270
mi
from 02139
Philadelphia, PA
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed With Major Depressive Disorder
Status: Enrolling
Updated: 8/30/2012
GSK Investigational Site
270
mi
from 02139
Philadelphia, PA
Click here to add this to my saved trials
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed With Major Depressive Disorder
Status: Enrolling
Updated:  8/30/2012
GSK Investigational Site
1124
mi
from 02139
Memphis, TN
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed With Major Depressive Disorder
Status: Enrolling
Updated: 8/30/2012
GSK Investigational Site
1124
mi
from 02139
Memphis, TN
Click here to add this to my saved trials
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed With Major Depressive Disorder
Status: Enrolling
Updated:  8/30/2012
GSK Investigational Site
855
mi
from 02139
Brown Deer, WI
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed With Major Depressive Disorder
Status: Enrolling
Updated: 8/30/2012
GSK Investigational Site
855
mi
from 02139
Brown Deer, WI
Click here to add this to my saved trials
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed With Major Depressive Disorder
Status: Enrolling
Updated:  8/30/2012
GSK Investigational Site
929
mi
from 02139
Madison, WI
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed With Major Depressive Disorder
Status: Enrolling
Updated: 8/30/2012
GSK Investigational Site
929
mi
from 02139
Madison, WI
Click here to add this to my saved trials
Single IV Dose of GLYX-13 in Patients With Treatment-Resistant Depression
Randomized, Double Blind, Placebo Controlled, Single IV Dose Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated:  9/10/2012
Mulitple
847
mi
from 02139
Evanston, IL
Single IV Dose of GLYX-13 in Patients With Treatment-Resistant Depression
Randomized, Double Blind, Placebo Controlled, Single IV Dose Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated: 9/10/2012
Mulitple
847
mi
from 02139
Evanston, IL
Click here to add this to my saved trials
Depression Outcomes Study of Exercise
Adapting Exercise Treatment for Depression to Adolescents: A Pilot Study
Status: Enrolling
Updated:  9/14/2012
Klein Buendel, Inc
1773
mi
from 02139
Golden, CO
Depression Outcomes Study of Exercise
Adapting Exercise Treatment for Depression to Adolescents: A Pilot Study
Status: Enrolling
Updated: 9/14/2012
Klein Buendel, Inc
1773
mi
from 02139
Golden, CO
Click here to add this to my saved trials
Stimulant Enhancement of Well-Being Therapy for Depression
Stimulant Enhancement of Well-Being Therapy for Depression
Status: Enrolling
Updated:  9/17/2012
Depression Clinical and Research Program
2
mi
from 02139
Boston, MA
Stimulant Enhancement of Well-Being Therapy for Depression
Stimulant Enhancement of Well-Being Therapy for Depression
Status: Enrolling
Updated: 9/17/2012
Depression Clinical and Research Program
2
mi
from 02139
Boston, MA
Click here to add this to my saved trials
Eszopiclone Co-Administered With Escitalopram for Insomnia in Elderly Adults With Major Depressive Disorder
Eszopiclone Co-Administered With Escitalopram for Insomnia in Elderly Adults With Major Depressive Disorder
Status: Enrolling
Updated:  10/2/2012
Lehigh Center for Clinical Research
259
mi
from 02139
Allentown, PA
Eszopiclone Co-Administered With Escitalopram for Insomnia in Elderly Adults With Major Depressive Disorder
Eszopiclone Co-Administered With Escitalopram for Insomnia in Elderly Adults With Major Depressive Disorder
Status: Enrolling
Updated: 10/2/2012
Lehigh Center for Clinical Research
259
mi
from 02139
Allentown, PA
Click here to add this to my saved trials
Pilot Study in Multi-Coil Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment Resistant Depression
Determining Effectiveness of Multi-Coil rTMS for Patients With Major Depressive Disorder: A Pilot Study
Status: Enrolling
Updated:  10/4/2012
Emory University
934
mi
from 02139
Atlanta, GA
Pilot Study in Multi-Coil Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment Resistant Depression
Determining Effectiveness of Multi-Coil rTMS for Patients With Major Depressive Disorder: A Pilot Study
Status: Enrolling
Updated: 10/4/2012
Emory University
934
mi
from 02139
Atlanta, GA
Click here to add this to my saved trials
Pilot Study in Multi-Coil Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment Resistant Depression
Determining Effectiveness of Multi-Coil rTMS for Patients With Major Depressive Disorder: A Pilot Study
Status: Enrolling
Updated:  10/4/2012
Rush Medical College
846
mi
from 02139
Chicago, IL
Pilot Study in Multi-Coil Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment Resistant Depression
Determining Effectiveness of Multi-Coil rTMS for Patients With Major Depressive Disorder: A Pilot Study
Status: Enrolling
Updated: 10/4/2012
Rush Medical College
846
mi
from 02139
Chicago, IL
Click here to add this to my saved trials
Pilot Study in Multi-Coil Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment Resistant Depression
Determining Effectiveness of Multi-Coil rTMS for Patients With Major Depressive Disorder: A Pilot Study
Status: Enrolling
Updated:  10/4/2012
Medical University of South Carolina
819
mi
from 02139
Charleston, SC
Pilot Study in Multi-Coil Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment Resistant Depression
Determining Effectiveness of Multi-Coil rTMS for Patients With Major Depressive Disorder: A Pilot Study
Status: Enrolling
Updated: 10/4/2012
Medical University of South Carolina
819
mi
from 02139
Charleston, SC
Click here to add this to my saved trials
Cognitive-behavioral Therapy vs. Light Therapy for Preventing SAD Recurrence
Cognitive-behavioral Therapy vs. Light Therapy for Preventing Seasonal Affective Disorder Recurrence
Status: Enrolling
Updated:  10/22/2012
University of Vermont, Psychology Department
180
mi
from 02139
Burlington, VT
Cognitive-behavioral Therapy vs. Light Therapy for Preventing SAD Recurrence
Cognitive-behavioral Therapy vs. Light Therapy for Preventing Seasonal Affective Disorder Recurrence
Status: Enrolling
Updated: 10/22/2012
University of Vermont, Psychology Department
180
mi
from 02139
Burlington, VT
Click here to add this to my saved trials
Cognitive Deficits in Major Depressive Disorder and Bipolar Disorder, Depressed Type: Prevalence and Improvement With Treatment of Depressive Symptoms
Cognitive Deficits in Major Depressive Disorder and Bipolar Disorder Depressed Type: Prevalence and Symptoms With Treating of Depressive Symptoms
Status: Enrolling
Updated:  11/2/2012
Massachusetts General Hospital
1
mi
from 02139
Boston, MA
Cognitive Deficits in Major Depressive Disorder and Bipolar Disorder, Depressed Type: Prevalence and Improvement With Treatment of Depressive Symptoms
Cognitive Deficits in Major Depressive Disorder and Bipolar Disorder Depressed Type: Prevalence and Symptoms With Treating of Depressive Symptoms
Status: Enrolling
Updated: 11/2/2012
Massachusetts General Hospital
1
mi
from 02139
Boston, MA
Click here to add this to my saved trials
Cognitive Behavioral Treatments for Depression in Chronic Illness
Cognitive Behavioral Treatments for Depression in Patients With Chronic Illness
Status: Enrolling
Updated:  11/15/2012
Glendale Adventist Medical Center
2584
mi
from 02139
Glendale, CA
Cognitive Behavioral Treatments for Depression in Chronic Illness
Cognitive Behavioral Treatments for Depression in Patients With Chronic Illness
Status: Enrolling
Updated: 11/15/2012
Glendale Adventist Medical Center
2584
mi
from 02139
Glendale, CA
Click here to add this to my saved trials
Cognitive Behavioral Treatments for Depression in Chronic Illness
Cognitive Behavioral Treatments for Depression in Patients With Chronic Illness
Status: Enrolling
Updated:  11/15/2012
Duke Univ Med Ctr
601
mi
from 02139
Durham, NC
Cognitive Behavioral Treatments for Depression in Chronic Illness
Cognitive Behavioral Treatments for Depression in Patients With Chronic Illness
Status: Enrolling
Updated: 11/15/2012
Duke Univ Med Ctr
601
mi
from 02139
Durham, NC
Click here to add this to my saved trials
Investigate Efficacy & Safety of RO4995819 vs. Placebo as Adjunct Tx in Patients w/Major Depressive Disorder
A Multi-center Randomized Double-blind Placebo-controlled Parallel-group Study to Investigate Efficacy and Safety of RO4995819 vs Placebo, as Adjunct Therapy in Patients w/Major Depressive Disorder
Status: Enrolling
Updated:  11/27/2012
Stanford University Department of Psychiatry
2687
mi
from 02139
Stanford, CA
Investigate Efficacy & Safety of RO4995819 vs. Placebo as Adjunct Tx in Patients w/Major Depressive Disorder
A Multi-center Randomized Double-blind Placebo-controlled Parallel-group Study to Investigate Efficacy and Safety of RO4995819 vs Placebo, as Adjunct Therapy in Patients w/Major Depressive Disorder
Status: Enrolling
Updated: 11/27/2012
Stanford University Department of Psychiatry
2687
mi
from 02139
Stanford, CA
Click here to add this to my saved trials
A Study in Prevention of Re-emergence of Depression Symptoms
LY2216684 Compared to Placebo as Adjunctive Therapy to SSRI in the Prevention of Symptom Re-emergence in Major Depressive Disorder
Status: Enrolling
Updated:  1/11/2013
Clinical Research Facility
2588
mi
from 02139
Los Angeles, CA
A Study in Prevention of Re-emergence of Depression Symptoms
LY2216684 Compared to Placebo as Adjunctive Therapy to SSRI in the Prevention of Symptom Re-emergence in Major Depressive Disorder
Status: Enrolling
Updated: 1/11/2013
Clinical Research Facility
2588
mi
from 02139
Los Angeles, CA
Click here to add this to my saved trials
A Study in Prevention of Re-emergence of Depression Symptoms
LY2216684 Compared to Placebo as Adjunctive Therapy to SSRI in the Prevention of Symptom Re-emergence in Major Depressive Disorder
Status: Enrolling
Updated:  1/11/2013
Clinical Research Facility
1256
mi
from 02139
Miami, FL
A Study in Prevention of Re-emergence of Depression Symptoms
LY2216684 Compared to Placebo as Adjunctive Therapy to SSRI in the Prevention of Symptom Re-emergence in Major Depressive Disorder
Status: Enrolling
Updated: 1/11/2013
Clinical Research Facility
1256
mi
from 02139
Miami, FL
Click here to add this to my saved trials
A Study in Prevention of Re-emergence of Depression Symptoms
LY2216684 Compared to Placebo as Adjunctive Therapy to SSRI in the Prevention of Symptom Re-emergence in Major Depressive Disorder
Status: Enrolling
Updated:  1/11/2013
Clinical Research Facility
882
mi
from 02139
Athens, GA
A Study in Prevention of Re-emergence of Depression Symptoms
LY2216684 Compared to Placebo as Adjunctive Therapy to SSRI in the Prevention of Symptom Re-emergence in Major Depressive Disorder
Status: Enrolling
Updated: 1/11/2013
Clinical Research Facility
882
mi
from 02139
Athens, GA
Click here to add this to my saved trials
A Study in Prevention of Re-emergence of Depression Symptoms
LY2216684 Compared to Placebo as Adjunctive Therapy to SSRI in the Prevention of Symptom Re-emergence in Major Depressive Disorder
Status: Enrolling
Updated:  1/11/2013
Clinical Research Facility
847
mi
from 02139
Chicago, IL
A Study in Prevention of Re-emergence of Depression Symptoms
LY2216684 Compared to Placebo as Adjunctive Therapy to SSRI in the Prevention of Symptom Re-emergence in Major Depressive Disorder
Status: Enrolling
Updated: 1/11/2013
Clinical Research Facility
847
mi
from 02139
Chicago, IL
Click here to add this to my saved trials
A Study in Prevention of Re-emergence of Depression Symptoms
LY2216684 Compared to Placebo as Adjunctive Therapy to SSRI in the Prevention of Symptom Re-emergence in Major Depressive Disorder
Status: Enrolling
Updated:  1/11/2013
Clinical Research Facility
802
mi
from 02139
Indianapolis, IN
A Study in Prevention of Re-emergence of Depression Symptoms
LY2216684 Compared to Placebo as Adjunctive Therapy to SSRI in the Prevention of Symptom Re-emergence in Major Depressive Disorder
Status: Enrolling
Updated: 1/11/2013
Clinical Research Facility
802
mi
from 02139
Indianapolis, IN
Click here to add this to my saved trials
A Study in Prevention of Re-emergence of Depression Symptoms
LY2216684 Compared to Placebo as Adjunctive Therapy to SSRI in the Prevention of Symptom Re-emergence in Major Depressive Disorder
Status: Enrolling
Updated:  1/11/2013
Clinical Research Facility
1304
mi
from 02139
Topeka, KA
A Study in Prevention of Re-emergence of Depression Symptoms
LY2216684 Compared to Placebo as Adjunctive Therapy to SSRI in the Prevention of Symptom Re-emergence in Major Depressive Disorder
Status: Enrolling
Updated: 1/11/2013
Clinical Research Facility
1304
mi
from 02139
Topeka, KA
Click here to add this to my saved trials